Security record · archived quarter
RZLT
Rezolute, Inc. · Healthcare · Biotechnology
1Tracked holders
0Δ holders
27.46KShares held
$127,433Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 27.46K | $127,433 | n/a | n/a |
| Q2 2026 | 64 | +3 | 50.24M | $261.09M | +9 | −6 |
| Q1 2026 | 63 | +7 | 53.20M | $162.23M | +14 | −7 |
| Q4 2025 | 56 | +1 | 61.70M | $145.62M | +3 | −2 |
| Q3 2025 | 14 | +1 | 31.48M | $295.95M | +2 | −1 |
| Q2 2025 | 10 | 0 | 26.66M | $118.90M | +2 | −2 |
| Q1 2025 | 7 | -1 | 3.87M | $11.23M | n/a | −1 |
| Q4 2024 | 8 | 0 | 4.74M | $23.24M | n/a | n/a |
| Q3 2024 | 7 | +1 | 2.88M | $13.99M | +1 | n/a |
| Q2 2024 | 6 | n/a | 2.25M | $9.69M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 27.46K | -20.9% | $127,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 124 holders, 86.21M shares, $263.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: BALYASNY ASSET MANAGEMENT L.P.
Aug 12
SC 13G: Dellora Investments LP
Aug 12
SC 13G/A: BANK OF AMERICA CORP /DE/
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API